Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Simon Laban
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04455-x, published online 31 May 2026. In the version of the article initially published, in the “Phase 1a dose escalation” column in Fig. 2, the fifth dose was listed as “0.054 mg” but should have been “0.54 mg”. This correction has been made to the HTML and PDF versions of the article.
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
|
Abstract IMA401 is a T cell receptor (TCR)-based next-generation bispecific T cell engaging receptor (TCER) targeting an HLA-A*02:01-presented peptide derived from MAGE-A4/MAGE-A8 with its high-affinity TCR-based domain, incorporating a low-affinity T-cell-recruiting domain and an optimized Fc domain to prolong half-life.
By Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Judith Hecker, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Manuel Ruh, Heiko Schuster, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Carsten Reinhardt, Stefanie Groepper, Mathias Haenel, Max-Felix Häring, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Olga Veremchuk, Cedrik Michael Britten
|
Nature
Verified
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
Discussion This is the first randomized double-blind phase 2 trial to evaluate the efficacy and safety of peltopepimut-S plus cemiplimab compared with cemiplimab alone as first-line or second-line therapy in R/M HPV16-positive HNSCC. The study did not meet its primary efficacy endpoint (ORR in FAS). Unexpectedly, the mOS was significantly lower in the peltopepimut-S arm compared with the control arm in the FAS.
Quantification of human papillomavirus cell-free DNA from low-volume blood plasma samples by digital PCR
Research ExplorerPublicationsQuantification of human papillomavirus cell-free DNA from lo... Abstract Bibliographical data
Immunotherapy for head and neck cancers: an update and future perspectives
ImmunotherapyVol. 11, No. 7 Commentary Johannes Doescher, Simon Laban, Patrick J Schuler, Cornelia Brunner & Thomas K Hoffmann Published Online:4 Apr 2019 References 1 Burtness B, Harrington KJ, Greil R et al. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann. Oncol. 29(Suppl_8), (2018).Crossref, Google Scholar 2 Hirschmann A, Lupatsch JEE, Schwenkglenks M et al.
New targeted therapies in spondyloarthritis: what are the limits?
Spondyloarthritis is a multifaceted chronic inflammatory disease, with predominantly axial involvement (sacroiliac joints and spine), with the possibility of peripheral involvement (synovitis, enthesitis and dactylitis) and extra-articular manifestations (uveitis, inflammatory bowel disease and psoriasis) [1–3].
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Simon
Contact Simon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack